LSL Pharma Group（LSL）株式概要LSL Pharma Group Inc.は、無菌医薬品、化粧品、自然健康食品の開発、製造、商業化をカナダ、米国、および国際的に行っている。 詳細LSL ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績2/6財務の健全性1/6配当金0/6報酬株価収益率（ 13.8 x） Canadian市場（ 16.3 x）を下回っています。今年は黒字化を達成 リスク分析利払いは収益で十分にカバーされない 最新の財務報告は6か月以上前のものである 意味のある時価総額がありません ( CA$38M )財務結果に影響を与える大きな一時的項目 すべてのリスクチェックを見るLSL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW492,858 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG492,858 investors already sharing narrativesYour Fair ValueCA$Current PriceCA$0.3255.6% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-10m86m2016201920222025202620282031Revenue CA$86.5mEarnings CA$9.0mAdvancedSet Fair ValueView all narrativesLSL Pharma Group Inc. 競合他社Cannara BiotechSymbol: TSX:LOVEMarket cap: CA$180.8mJamieson WellnessSymbol: TSX:JWELMarket cap: CA$1.7bRecode StudiosSymbol: BSE:544755Market cap: ₹2.2bBiome AustraliaSymbol: ASX:BIOMarket cap: AU$65.0m価格と性能株価の高値、安値、推移の概要LSL Pharma Group過去の株価現在の株価CA$0.3252週高値CA$0.5652週安値CA$0.30ベータ-0.471ヶ月の変化-4.55%3ヶ月変化-19.23%1年変化-26.74%3年間の変化-25.00%5年間の変化n/aIPOからの変化-58.00%最新ニュースNew Risk • Jun 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.5x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (CA$40.0m market cap, or US$28.7m).お知らせ • Apr 15LSL Pharma Group Inc., Annual General Meeting, Jun 19, 2026LSL Pharma Group Inc., Annual General Meeting, Jun 19, 2026.お知らせ • Jan 28LSL Pharma Group Inc. Successfully Obtained U.S. FDA Certification for the Manufacturing of Ophthalmic Ointments for Commercialization in the United StatesLSL PHARMA GROUP INC. announced that it has secured certification from the U.S. Food and Drug Administration (FDA) for its ophthalmic ointment manufacturing activities. The ophthalmic product Avaclyr, manufactured by LSL Pharma's subsidiary, Steri-Med Pharma Inc. ("Steri-Med"), and to be marketed by U.S.-based Fera Pharmaceuticals LLC, has received FDA approval for commercialization in the United States. The certification of the Steri-Med's manufacturing site allows LSL Pharma to manufacture and potentially commercialize additional ophthalmic ointment products for commercialization in the U.S. market. The certification follows a successful FDA inspection of Steri-Med's facility, confirming full compliance with current Good Manufacturing Practices (cGMP). The Company believes this regulatory milestone significantly strengthens its competitive positioning, enhances future revenue diversification, and establishes a clear pathway for sustainable growth and long-term value creation for shareholders. With this FDA certification, LSL Pharma is well positioned to leverage its upcoming plan to significantly expand its manufacturing capacity to support U.S. market demand for specialized ophthalmic product development and manufacturing projects.分析記事 • Nov 27Potential Upside For LSL Pharma Group Inc. (CVE:LSL) Not Without RiskWith a median price-to-sales (or "P/S") ratio of close to 1.9x in the Personal Products industry in Canada, you could...Reported Earnings • Nov 26Third quarter 2025 earnings released: CA$0.01 loss per share (vs CA$0.003 loss in 3Q 2024)Third quarter 2025 results: CA$0.01 loss per share (further deteriorated from CA$0.003 loss in 3Q 2024). Revenue: CA$7.58m (up 89% from 3Q 2024). Net loss: CA$1.18m (loss widened 206% from 3Q 2024).お知らせ • Nov 19LSL Pharma Group Inc. (TSXV:LSL) acquired Laboratoire Du-Var Inc. for CAD 3.2 million.LSL Pharma Group Inc. (TSXV:LSL) acquired Laboratoire Du-Var Inc. for CAD 3.2 million on November 17, 2025. For the 12-month period ended on August 31, 2025, Du-Var generated Adjusted EBITDA of $0.5 million, from $4.4 million of revenues. As at August 31, 2025, Du-Var had total assets of $6.9 million. LSL Pharma Group Inc. (TSXV:LSL) completed the acquisition of Laboratoire Du-Var Inc. for CAD 3.2 million on November 17, 2025.最新情報をもっと見るRecent updatesNew Risk • Jun 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.5x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (CA$40.0m market cap, or US$28.7m).お知らせ • Apr 15LSL Pharma Group Inc., Annual General Meeting, Jun 19, 2026LSL Pharma Group Inc., Annual General Meeting, Jun 19, 2026.お知らせ • Jan 28LSL Pharma Group Inc. Successfully Obtained U.S. FDA Certification for the Manufacturing of Ophthalmic Ointments for Commercialization in the United StatesLSL PHARMA GROUP INC. announced that it has secured certification from the U.S. Food and Drug Administration (FDA) for its ophthalmic ointment manufacturing activities. The ophthalmic product Avaclyr, manufactured by LSL Pharma's subsidiary, Steri-Med Pharma Inc. ("Steri-Med"), and to be marketed by U.S.-based Fera Pharmaceuticals LLC, has received FDA approval for commercialization in the United States. The certification of the Steri-Med's manufacturing site allows LSL Pharma to manufacture and potentially commercialize additional ophthalmic ointment products for commercialization in the U.S. market. The certification follows a successful FDA inspection of Steri-Med's facility, confirming full compliance with current Good Manufacturing Practices (cGMP). The Company believes this regulatory milestone significantly strengthens its competitive positioning, enhances future revenue diversification, and establishes a clear pathway for sustainable growth and long-term value creation for shareholders. With this FDA certification, LSL Pharma is well positioned to leverage its upcoming plan to significantly expand its manufacturing capacity to support U.S. market demand for specialized ophthalmic product development and manufacturing projects.分析記事 • Nov 27Potential Upside For LSL Pharma Group Inc. (CVE:LSL) Not Without RiskWith a median price-to-sales (or "P/S") ratio of close to 1.9x in the Personal Products industry in Canada, you could...Reported Earnings • Nov 26Third quarter 2025 earnings released: CA$0.01 loss per share (vs CA$0.003 loss in 3Q 2024)Third quarter 2025 results: CA$0.01 loss per share (further deteriorated from CA$0.003 loss in 3Q 2024). Revenue: CA$7.58m (up 89% from 3Q 2024). Net loss: CA$1.18m (loss widened 206% from 3Q 2024).お知らせ • Nov 19LSL Pharma Group Inc. (TSXV:LSL) acquired Laboratoire Du-Var Inc. for CAD 3.2 million.LSL Pharma Group Inc. (TSXV:LSL) acquired Laboratoire Du-Var Inc. for CAD 3.2 million on November 17, 2025. For the 12-month period ended on August 31, 2025, Du-Var generated Adjusted EBITDA of $0.5 million, from $4.4 million of revenues. As at August 31, 2025, Du-Var had total assets of $6.9 million. LSL Pharma Group Inc. (TSXV:LSL) completed the acquisition of Laboratoire Du-Var Inc. for CAD 3.2 million on November 17, 2025.お知らせ • Oct 29Health Canada Grants LSL Pharma Group Inc. to Commercialize Six New Sterile Ophthalmic SolutionsLSL Pharma Group Inc. announced that Health Canada has approved its first six (6) sterile ophthalmic solutions for the treatment of glaucoma and allergies. The commercial launch of these products is expected to begin in the second quarter of 2026. This approval is a significant strategic milestone for LSL Pharma, strengthening its presence in the sterile ophthalmic pharmaceuticals sector and demonstrating the Company's ability to successfully complete complex projects in compliance with Canadian regulatory standards. These six (6) ophthalmic products have an aggregate commercial markets of $66 million in Canada (IQVIA 2025 data). The addition of these eye care products and their launch are part of LSL Pharma's overall strategy to diversify its offering of high value-added products targeting specialized therapeutic segments.お知らせ • Oct 16LSL Pharma Group Inc. Announces Board ChangesLSL Pharma Group Inc. announced the appointment of Mr. Louis Laflamme as chairman of the board of directors and the appointment of Mr. Noureddine Mokaddem as a new member of the board of directors. A member of the board since April 2025, Mr. Laflamme succeeds Mr. François Roberge as independent Chairman of the Board and brings to this new role extensive experience and understanding of the Company's activities and vision. In connection with his appointment, Mr. Laflamme, who no longer provides services to the Company under the Services Agreement referred to in the news release dated March 31, 2025, is now considered by the Company as an independent director. Mr. Roberge will remain a member of the Board of Directors while continuing to exercise his leadership as President and Chief Executive Officer of LSL Pharma.Mr. Noureddine Mokaddem has extensive experience with several private and publicly traded companies, primarily in Europe and North America and joins the Company's Board as an independent director. Among other things, he will help strengthen the Company's strategic governance and support its long-term growth ambitions.Mr. Laflamme is a member of the CPA Order and holds a BBA from Laval University. He is President and CEO of Antégrade Medical Inc., an innovative company dedicated to the development of medical devices for cardiology applications using the antegrade approach to treat patients with advanced cardiovascular diseases that are currently difficult to treat. Previously, he was President, Chief Executive Officer, and Director of OpSens Inc. from 2013 to 2024, when the company was sold. During this period, OpSens revolutionized certain practices in interventional cardiology with medical devices. He currently serves on the boards of directors of MY01 Inc., Icentia, and EMKA SCIREQ Inc.Mr. Mokaddem, engineer, is an international development specialist with nearly 42 years of professional experience in the Kingdom of Morocco, Africa, and North America. He invests primarily in the industrial, mining, real estate, energy, and other sectors, as well as in partnership projects. In Morocco and internationally, he has successfully completed all stages of implementation for a wide variety of projects, from feasibility studies to the start-up of production units of various sizes, including the maintenance of complex units, functional departments, and distribution networks. During his career, he has also been involved in numerous private and publicly traded companies. Founder, President & CEO and Chairman of the Board of Directors of Aya Gold & Silver from 2010 to 2020. Since July 2024, he has been a member of the Board of Directors of Abcourt Mines.分析記事 • Sep 02LSL Pharma Group's (CVE:LSL) Solid Profits Have Weak FundamentalsDespite announcing strong earnings, LSL Pharma Group Inc.'s ( CVE:LSL ) stock was sluggish. Our analysis uncovered some...お知らせ • Sep 02LSL Pharma Group Inc. announced that it has received CAD 2.275 million in fundingLSL Pharma Group Inc. announced a non-brokered private placement of 5,687,500 units at a price of CAD 0.40 or gross proceeds of CAD 2,275,000 on September 2, 2025.Each Unit consists of one class A share of the Corporation and one Common Share purchase warrant. Each Warrant entitles the holder, subject to adjustments in certain cases, to purchase one Common Share at a price of CAD 0.70 for a period of 24 months following the closing of the Financing. The transaction included participation from François Roberge, President and CEO and Mario Paradis, a director of the Corporation have subscribed for 187,500 Units and 125,000 Units respectively pursuant to the Financing. In connection with this Financing, the company paid to a finder dealing at arm's length with the Corporation, finder's fees for a total of CAD 23,750 in cash and issued 59,375 finder's warrants. Each Finder's Warrant entitles the holder to purchase one Common Share at a price of CAD 0.70 for a period of 12 months following the closing of the Financing. Each Unit, Common Share, Warrant, Warrant Share, Finder's Warrant and Common Share issued upon the exercise of the Finder's Warrant will be subject to a four month hold period under the applicable securities laws. The Financing is subject to the regulatory approval of the TSX Venture Exchange.Reported Earnings • Aug 26Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: CA$7.22m (up 72% from 2Q 2024). Net loss: CA$389.0k (loss narrowed 25% from 2Q 2024).New Risk • May 09New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.2x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). High level of non-cash earnings (24% accrual ratio). Minor Risk Market cap is less than US$100m (CA$45.6m market cap, or US$32.8m).分析記事 • May 02Shareholders Should Be Pleased With LSL Pharma Group Inc.'s (CVE:LSL) PriceWhen close to half the companies in the Personal Products industry in Canada have price-to-sales ratios (or "P/S...お知らせ • Apr 09LSL Pharma Group Inc., Annual General Meeting, Jun 27, 2025LSL Pharma Group Inc., Annual General Meeting, Jun 27, 2025.お知らせ • Mar 31LSL Pharma Group Appoints Louis Laflamme to the Board of DirectorsLSL PHARMA GROUP INC announce the appointment of Louis Laflamme as a member of the board of directors. Mr. Louis Laflamme is Entrepreneur in Residence for Medtech Ventures Fund of Sectoral Asset Management Inc. Previously, he was President, CEO and director of OpSens Inc. from January 2013 to March 2024, when it was acquired by Haemonetics for $345 million. During this period, the company revolutionized certain practices in interventional cardiology with medical instruments. From November 2005 to December 2012, he served as Chief Financial Officer and Corporate Secretary of OpSens. He also serves on the board of directors of SiliCycle, MY01 Inc., Icentia and EMKA SCIREQ Inc. He also held leadership positions in other technology companies. Mr. Laflamme is a member of the Order of Chartered Professional Accountants of Quebec. He holds a Bachelor's degree in Business Administration from Laval University.New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$43.3m market cap, or US$30.2m).お知らせ • Dec 20LSL Pharma Group Inc. announced that it has received CAD 1 million in fundingLSL Pharma Group Inc. announced a private placement of unsecured promissory notes for a gross proceeds of CAD 1 million on December 18, 2024. The transaction included participation from new investor, Luc Mainville. The Notes are unsecured, non-convertible, bear interest at a blended rate of 13% and mature on January 1, 2028. The company has also issued 2,000,000 warrants in connection with the Notes, with each Warrant entitling the holder to purchase one common share of the Corporation at a price equal to the greater of CAD 0.70 or the closing price of the company on December 20, 2024 , for a period of 36 months following the closing of the Financing. The Notes may be redeemed by the Corporation at any time on or after January 1, 2026. Each Warrant and Warrant share will be subject to a four-month hold period under the applicable securities laws. The Financing is subject to the TSX Venture Exchange's approval. There were no finders involved with the Financing.お知らせ • Dec 19LSL Pharma Group Inc. (TSXV:LSL) acquired Dermolab Pharma Ltd. for CAD 4 million.LSL Pharma Group Inc. (TSXV:LSL) acquired Dermolab Pharma Ltd. for CAD 4 million on December 17, 2024. The total consideration for the transaction includes (i) the renewal of Dermolab's operating line of credit and term loan totaling a maximum of $3 million and (ii) a cash payment of $955,000 on closing, subject to post-closing adjustments. The cash portion of the purchase price was financed by the proceeds of the CAD 2 million concurrent notes offering. For the period ending August 31, 2024, Dermolab Pharma Ltd. reported total revenue of CAD 10.1 million and EBITDA of CAD 0.5 million. As of August 31, 2024, Dermolab Pharma Ltd. reported total assets of CAD 7.9 million. Robert Boisvert, Dermolab's prior President has been retained for an interim period. The transaction is accretive, expected to boost revenues by approximately 40%. LSL Pharma Group Inc. (TSXV:LSL) completed the acquisition of Dermolab Pharma Ltd. for CAD 4 million on December 17, 2024.お知らせ • Dec 18LSL Pharma Group Inc. Appoints Guy Paul Allard as Corporate SecretaryLSL PHARMA GROUP INC announced the appointment of Guy Paul Allard as Vice President, Legal Affairs and Corporate Secretary. A seasoned lawyer specializing in corporate and securities law for over 25 years, Mr. Allard has practiced in national and global law firms and has previously held similar executive in-house positions in the pharmaceutical industry.分析記事 • Dec 14Not Many Are Piling Into LSL Pharma Group Inc. (CVE:LSL) Stock Yet As It Plummets 26%The LSL Pharma Group Inc. ( CVE:LSL ) share price has fared very poorly over the last month, falling by a substantial...New Risk • Dec 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$5.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$5.7m free cash flow). Earnings have declined by 26% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (CA$47.4m market cap, or US$33.8m).お知らせ • Nov 07LSL Pharma Group Announces Completion of Steri-Med Pharma's Phase 1 Production Scale UpLSL Pharma Group Inc. announced having completed the initial phase of production scale-up at its Steri-Med Pharma ("Steri-Med") plan. The initial phase of production scale up has contributed to more than double the plant capacity compared to 2023 levels, and enabled Steri-Med to win new international contracts for its existing products. The second phase of production scale-up will include the installation of a new fully automated sterile ointment production line (the "Second Line"). The Second Line is expected to be delivered during the first quarter of 2025 and to be operational early 2026, following installation and validation.Reported Earnings • Aug 27Second quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.038 loss in 2Q 2023)Second quarter 2024 results: CA$0.007 loss per share (improved from CA$0.038 loss in 2Q 2023). Revenue: CA$4.19m (up 106% from 2Q 2023). Net loss: CA$516.0k (loss narrowed 83% from 2Q 2023).お知らせ • Jul 15LSL Pharma Group Inc. announced that it has received CAD 2.4508 million in fundingOn July 15, 2024, LSL Pharma Group Inc closed the transaction. The company issued 2,400,000 units at a price of CAD 0.4 per Unit for total gross proceeds of CAD 960,000 in its final tranche. The Corporation was thus able to raise with both tranches a total of $2,450,800 in Financing. In connection with this second and final tranche of the Financing, the Corporation paid to finders dealing at arm’s length with the Corporation, finders’ fees for a total of CAD 14,600 in cash and issued 36,500 finders’ warrants. Each Finder’s Warrant entitles the holder to purchase one (1) Common Share at a price of CAD 0.70 for a period of 18 months following the closing date.お知らせ • Jun 06LSL Pharma Group Inc. announced that it expects to receive CAD 3 million in fundingLSL Pharma Group Inc announced a non-brokered private placement financing of 7,500,000 units at issue price CAD 0.4 per share for gross proceeds CAD 3,000,000 on June 5, 2024. Each Unit consist of one class A share of the Corporation and one Common Share purchase warrant. Each Warrant will entitle the holder, subject to adjustments in certain cases, to purchase one Common Share at a price of CAD 0.70 for a period of 24 months following the closing of the Financing. Each issued Unit, Common Share, Warrant, Warrant Share, Finder’s Warrant and Common Share issued upon the exercise of the Finder’s Warrant will be subject to a four month hold period under the applicable securities laws. The Financing and the Units for Debts are subject to the regulatory approvals, including the TSX Venture Exchange.お知らせ • May 18LSL Pharma Group Inc., Annual General Meeting, Jun 28, 2024LSL Pharma Group Inc., Annual General Meeting, Jun 28, 2024.お知らせ • Apr 24LSL Pharma Group Inc. announced that it has received CAD 6.479426 million in funding from Alfera Pharmaceuticals, LLCOn April 24, 2024, LSL Pharma Group Inc. closed the transaction. The company has now issued 9,485,000 units at an issue price of CAD 0.40 per unit for the gross proceeds of CAD 3,794,000 in its second and final tranche closing bringing the total gross proceeds raised from the private placement to CAD 6,479,426. The company has now issued total 16,198,565 units for total gross proceeds of CAD 6,479,426 in the transaction. In connection with this transaction, the company paid to a finder dealing at arm’s length with the company, finders’ fees for a total of CAD 30,000 in cash and issued 75,000 finders’ warrants. Each Finder’s Warrant entitles the holder to purchase one common share at a price of CAD 0.70 for a period of 18 months following the closing of the transaction. Each issued unit, Common Share, Warrant, Warrant Share, Finder’s Warrant and Common Share underlying the Finder’s Warrants will be subject to a four month hold period under the applicable securities laws. The transaction is subject to the final approval of the TSX Venture Exchange. The transaction included participation from new investor Alfera Pharmaceuticals, LLC for 1,250,000 Units for an aggregate subscription price of CAD 500,000. Its direct or indirect holding, inclusive of Della Fera’s holding, on a non-diluted basis, was 0.04% prior to the financing and reaches now 1.20% following the financing while, on a partially diluted basis, was of 0.32% prior to the financing and reaches now 2.57%.お知らせ • Apr 23LSL PHARMA GROUP INC Appoints Diane Beaudry and Mario Paradis to Its Board of DirectorsLSL PHARMA GROUP INC announced the appointment of Diane Beaudry and Mario Paradis to its Board of Directors.New Risk • Mar 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (CA$37.9m market cap, or US$27.9m).お知らせ • Mar 07LSL Pharma Group Inc. announced that it expects to receive CAD 3.5 million in fundingLSL Pharma Group announced a non brokered private placement financing of Units for the minimum of 6,250,000 units and maximum of 8,750,000 at an issue price of CAD 0.40 per unit for the minimum gross proceeds of CAD 2,500,000 and maximum of CAD 3,500,000 on March 7, 2024. Each unit will consists of one class A common share and one common share purchase warrant. Each Warrant will entitle the holder, subject to adjustments in certain cases, to purchase one Common Share at a price of CAD 0.70 for a period of 36 months following the closing of the Financing. the Corporation may pay finders’ fees of up to 5% of the gross proceeds raised from investors introduced to the Corporation by a finder, payable in cash; and finders’ warrants of up to 5% of the number of Units issued to investors introduced to the Corporation by a finder. Each Finder’s Warrant will entitle the holder, subject to adjustments in certain cases, to purchase one Common Share at a price of CAD 0.70 for a period of 18 months following the closing of the Financing. Each issued Unit, Common Share, Warrant, Warrant Share, Finder’s Warrant and Common Share issued upon the exercise of the Finder’s Warrant will be subject to a four month hold period under the applicable securities laws. The Financing and the Units for Debts are subject to the regulatory approvals, including the TSX Venture Exchange.お知らせ • Dec 07LSL Pharma Group Inc., Annual General Meeting, Jan 26, 2024LSL Pharma Group Inc., Annual General Meeting, Jan 26, 2024.お知らせ • Dec 04+ 1 more updateLSL Pharma Group Inc. Appoints Luc Mainville as Senior Vice President, Effective December 4, 2023LSL PHARMA GROUP INC announced the appointment of Mr. Luc Mainville as Senior Vice President and Chief Financial Officer effective December 4, 2023. Mr. Mainville brings extensive experience in the capital markets and life sciences industry. He is recognized for his financial and operational leadership having been associated with several fast-growing companies. In an executive management career spanning more than 30 years, he has been involved in numerous public and private financings totalling in excess of $500 million and more than 50 corporate transactions, including initial public offerings, licensing, as well as mergers and acquisitions. Over the last five years, Mr. Mainville acted as Senior Vice President and Chief Financial Officer of Valeo Pharma, a fast-growing Canadian pharmaceutical company. During his tenure at Valeo, he raised in excess of $100 million helping Valeo increase its revenues 15 fold. Prior to that, he held senior management positions with various life sciences companies, including Acerus Pharma, Cardiome Pharma, Neopharm Labs and LAB Research. Prior to his career in the life sciences sector, he was partner with KPMG, LLP. He holds an MBA from McGill University. Luc Mainville has been Director of LSL Pharma since February 2023, and will relinquish his board position when joining the Company.Reported Earnings • Dec 03Third quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.023 loss in 3Q 2022)Third quarter 2023 results: CA$0.009 loss per share (improved from CA$0.023 loss in 3Q 2022). Revenue: CA$2.51m (down 4.9% from 3Q 2022). Net loss: CA$762.3k (loss narrowed 48% from 3Q 2022).お知らせ • Sep 01LSL Pharma Group Inc. Announces Executive Changes, Effective August 31, 2023LSL Pharma Group announced the departure of Sylvain Richer, Chief Financial Officer, for personal reasons and to seek new opportunities, effective August 31, 2023. The Company has begun a process to find a successor. Untilthen, François Roberge will assume the interim and Mr. Richer will remain available to ensure a smooth transition.New Risk • Aug 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.2m free cash flow). Revenue has declined by 6.3% over the past year. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (CA$33.7m market cap, or US$24.9m).New Risk • Jul 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 7.6% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (CA$35.4m market cap, or US$26.7m).Board Change • Mar 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Luc Mainville was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.株主還元LSLCA Personal ProductsCA 市場7D5.0%2.9%0.3%1Y-26.7%16.6%29.2%株主還元を見る業界別リターン: LSL過去 1 年間で16.6 % の収益を上げたCanadian Personal Products業界を下回りました。リターン対市場: LSLは、過去 1 年間で29.2 % のリターンを上げたCanadian市場を下回りました。価格変動Is LSL's price volatile compared to industry and market?LSL volatilityLSL Average Weekly Movement5.0%Personal Products Industry Average Movement8.0%Market Average Movement9.6%10% most volatile stocks in CA Market16.5%10% least volatile stocks in CA Market3.7%安定した株価: LSL 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: LSLの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/a185Francois Robergewww.groupelslpharma.com無菌医薬品、化粧品、自然健康食品の開発、製造、商業化をカナダ、米国、および国際的に行っている。錠剤やカプセルの栄養補助食品やビタミン剤、軟膏や点滴のニッチな無菌眼科製品、薬局や病院向けの液体や半固体の化粧品、医薬品、自然健康製品を提供している。本社はカナダのブーシェビルにある。もっと見るLSL Pharma Group Inc. 基礎のまとめLSL Pharma Group の収益と売上を時価総額と比較するとどうか。LSL 基礎統計学時価総額CA$38.18m収益（TTM）CA$2.78m売上高(TTM)CA$26.80m13.8xPER（株価収益率1.4xP/SレシオLSL は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計LSL 損益計算書（TTM）収益CA$26.80m売上原価CA$18.83m売上総利益CA$7.97mその他の費用CA$5.20m収益CA$2.78m直近の収益報告Sep 30, 2025次回決算日該当なし一株当たり利益（EPS）0.023グロス・マージン29.73%純利益率10.35%有利子負債／自己資本比率85.1%LSL の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/03 23:08終値2026/07/03 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋LSL Pharma Group Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Jun 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.5x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (CA$40.0m market cap, or US$28.7m).
お知らせ • Apr 15LSL Pharma Group Inc., Annual General Meeting, Jun 19, 2026LSL Pharma Group Inc., Annual General Meeting, Jun 19, 2026.
お知らせ • Jan 28LSL Pharma Group Inc. Successfully Obtained U.S. FDA Certification for the Manufacturing of Ophthalmic Ointments for Commercialization in the United StatesLSL PHARMA GROUP INC. announced that it has secured certification from the U.S. Food and Drug Administration (FDA) for its ophthalmic ointment manufacturing activities. The ophthalmic product Avaclyr, manufactured by LSL Pharma's subsidiary, Steri-Med Pharma Inc. ("Steri-Med"), and to be marketed by U.S.-based Fera Pharmaceuticals LLC, has received FDA approval for commercialization in the United States. The certification of the Steri-Med's manufacturing site allows LSL Pharma to manufacture and potentially commercialize additional ophthalmic ointment products for commercialization in the U.S. market. The certification follows a successful FDA inspection of Steri-Med's facility, confirming full compliance with current Good Manufacturing Practices (cGMP). The Company believes this regulatory milestone significantly strengthens its competitive positioning, enhances future revenue diversification, and establishes a clear pathway for sustainable growth and long-term value creation for shareholders. With this FDA certification, LSL Pharma is well positioned to leverage its upcoming plan to significantly expand its manufacturing capacity to support U.S. market demand for specialized ophthalmic product development and manufacturing projects.
分析記事 • Nov 27Potential Upside For LSL Pharma Group Inc. (CVE:LSL) Not Without RiskWith a median price-to-sales (or "P/S") ratio of close to 1.9x in the Personal Products industry in Canada, you could...
Reported Earnings • Nov 26Third quarter 2025 earnings released: CA$0.01 loss per share (vs CA$0.003 loss in 3Q 2024)Third quarter 2025 results: CA$0.01 loss per share (further deteriorated from CA$0.003 loss in 3Q 2024). Revenue: CA$7.58m (up 89% from 3Q 2024). Net loss: CA$1.18m (loss widened 206% from 3Q 2024).
お知らせ • Nov 19LSL Pharma Group Inc. (TSXV:LSL) acquired Laboratoire Du-Var Inc. for CAD 3.2 million.LSL Pharma Group Inc. (TSXV:LSL) acquired Laboratoire Du-Var Inc. for CAD 3.2 million on November 17, 2025. For the 12-month period ended on August 31, 2025, Du-Var generated Adjusted EBITDA of $0.5 million, from $4.4 million of revenues. As at August 31, 2025, Du-Var had total assets of $6.9 million. LSL Pharma Group Inc. (TSXV:LSL) completed the acquisition of Laboratoire Du-Var Inc. for CAD 3.2 million on November 17, 2025.
New Risk • Jun 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.5x net interest cover). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Large one-off items impacting financial results. Market cap is less than US$100m (CA$40.0m market cap, or US$28.7m).
お知らせ • Apr 15LSL Pharma Group Inc., Annual General Meeting, Jun 19, 2026LSL Pharma Group Inc., Annual General Meeting, Jun 19, 2026.
お知らせ • Jan 28LSL Pharma Group Inc. Successfully Obtained U.S. FDA Certification for the Manufacturing of Ophthalmic Ointments for Commercialization in the United StatesLSL PHARMA GROUP INC. announced that it has secured certification from the U.S. Food and Drug Administration (FDA) for its ophthalmic ointment manufacturing activities. The ophthalmic product Avaclyr, manufactured by LSL Pharma's subsidiary, Steri-Med Pharma Inc. ("Steri-Med"), and to be marketed by U.S.-based Fera Pharmaceuticals LLC, has received FDA approval for commercialization in the United States. The certification of the Steri-Med's manufacturing site allows LSL Pharma to manufacture and potentially commercialize additional ophthalmic ointment products for commercialization in the U.S. market. The certification follows a successful FDA inspection of Steri-Med's facility, confirming full compliance with current Good Manufacturing Practices (cGMP). The Company believes this regulatory milestone significantly strengthens its competitive positioning, enhances future revenue diversification, and establishes a clear pathway for sustainable growth and long-term value creation for shareholders. With this FDA certification, LSL Pharma is well positioned to leverage its upcoming plan to significantly expand its manufacturing capacity to support U.S. market demand for specialized ophthalmic product development and manufacturing projects.
分析記事 • Nov 27Potential Upside For LSL Pharma Group Inc. (CVE:LSL) Not Without RiskWith a median price-to-sales (or "P/S") ratio of close to 1.9x in the Personal Products industry in Canada, you could...
Reported Earnings • Nov 26Third quarter 2025 earnings released: CA$0.01 loss per share (vs CA$0.003 loss in 3Q 2024)Third quarter 2025 results: CA$0.01 loss per share (further deteriorated from CA$0.003 loss in 3Q 2024). Revenue: CA$7.58m (up 89% from 3Q 2024). Net loss: CA$1.18m (loss widened 206% from 3Q 2024).
お知らせ • Nov 19LSL Pharma Group Inc. (TSXV:LSL) acquired Laboratoire Du-Var Inc. for CAD 3.2 million.LSL Pharma Group Inc. (TSXV:LSL) acquired Laboratoire Du-Var Inc. for CAD 3.2 million on November 17, 2025. For the 12-month period ended on August 31, 2025, Du-Var generated Adjusted EBITDA of $0.5 million, from $4.4 million of revenues. As at August 31, 2025, Du-Var had total assets of $6.9 million. LSL Pharma Group Inc. (TSXV:LSL) completed the acquisition of Laboratoire Du-Var Inc. for CAD 3.2 million on November 17, 2025.
お知らせ • Oct 29Health Canada Grants LSL Pharma Group Inc. to Commercialize Six New Sterile Ophthalmic SolutionsLSL Pharma Group Inc. announced that Health Canada has approved its first six (6) sterile ophthalmic solutions for the treatment of glaucoma and allergies. The commercial launch of these products is expected to begin in the second quarter of 2026. This approval is a significant strategic milestone for LSL Pharma, strengthening its presence in the sterile ophthalmic pharmaceuticals sector and demonstrating the Company's ability to successfully complete complex projects in compliance with Canadian regulatory standards. These six (6) ophthalmic products have an aggregate commercial markets of $66 million in Canada (IQVIA 2025 data). The addition of these eye care products and their launch are part of LSL Pharma's overall strategy to diversify its offering of high value-added products targeting specialized therapeutic segments.
お知らせ • Oct 16LSL Pharma Group Inc. Announces Board ChangesLSL Pharma Group Inc. announced the appointment of Mr. Louis Laflamme as chairman of the board of directors and the appointment of Mr. Noureddine Mokaddem as a new member of the board of directors. A member of the board since April 2025, Mr. Laflamme succeeds Mr. François Roberge as independent Chairman of the Board and brings to this new role extensive experience and understanding of the Company's activities and vision. In connection with his appointment, Mr. Laflamme, who no longer provides services to the Company under the Services Agreement referred to in the news release dated March 31, 2025, is now considered by the Company as an independent director. Mr. Roberge will remain a member of the Board of Directors while continuing to exercise his leadership as President and Chief Executive Officer of LSL Pharma.Mr. Noureddine Mokaddem has extensive experience with several private and publicly traded companies, primarily in Europe and North America and joins the Company's Board as an independent director. Among other things, he will help strengthen the Company's strategic governance and support its long-term growth ambitions.Mr. Laflamme is a member of the CPA Order and holds a BBA from Laval University. He is President and CEO of Antégrade Medical Inc., an innovative company dedicated to the development of medical devices for cardiology applications using the antegrade approach to treat patients with advanced cardiovascular diseases that are currently difficult to treat. Previously, he was President, Chief Executive Officer, and Director of OpSens Inc. from 2013 to 2024, when the company was sold. During this period, OpSens revolutionized certain practices in interventional cardiology with medical devices. He currently serves on the boards of directors of MY01 Inc., Icentia, and EMKA SCIREQ Inc.Mr. Mokaddem, engineer, is an international development specialist with nearly 42 years of professional experience in the Kingdom of Morocco, Africa, and North America. He invests primarily in the industrial, mining, real estate, energy, and other sectors, as well as in partnership projects. In Morocco and internationally, he has successfully completed all stages of implementation for a wide variety of projects, from feasibility studies to the start-up of production units of various sizes, including the maintenance of complex units, functional departments, and distribution networks. During his career, he has also been involved in numerous private and publicly traded companies. Founder, President & CEO and Chairman of the Board of Directors of Aya Gold & Silver from 2010 to 2020. Since July 2024, he has been a member of the Board of Directors of Abcourt Mines.
分析記事 • Sep 02LSL Pharma Group's (CVE:LSL) Solid Profits Have Weak FundamentalsDespite announcing strong earnings, LSL Pharma Group Inc.'s ( CVE:LSL ) stock was sluggish. Our analysis uncovered some...
お知らせ • Sep 02LSL Pharma Group Inc. announced that it has received CAD 2.275 million in fundingLSL Pharma Group Inc. announced a non-brokered private placement of 5,687,500 units at a price of CAD 0.40 or gross proceeds of CAD 2,275,000 on September 2, 2025.Each Unit consists of one class A share of the Corporation and one Common Share purchase warrant. Each Warrant entitles the holder, subject to adjustments in certain cases, to purchase one Common Share at a price of CAD 0.70 for a period of 24 months following the closing of the Financing. The transaction included participation from François Roberge, President and CEO and Mario Paradis, a director of the Corporation have subscribed for 187,500 Units and 125,000 Units respectively pursuant to the Financing. In connection with this Financing, the company paid to a finder dealing at arm's length with the Corporation, finder's fees for a total of CAD 23,750 in cash and issued 59,375 finder's warrants. Each Finder's Warrant entitles the holder to purchase one Common Share at a price of CAD 0.70 for a period of 12 months following the closing of the Financing. Each Unit, Common Share, Warrant, Warrant Share, Finder's Warrant and Common Share issued upon the exercise of the Finder's Warrant will be subject to a four month hold period under the applicable securities laws. The Financing is subject to the regulatory approval of the TSX Venture Exchange.
Reported Earnings • Aug 26Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: CA$7.22m (up 72% from 2Q 2024). Net loss: CA$389.0k (loss narrowed 25% from 2Q 2024).
New Risk • May 09New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.2x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.2x net interest cover). High level of non-cash earnings (24% accrual ratio). Minor Risk Market cap is less than US$100m (CA$45.6m market cap, or US$32.8m).
分析記事 • May 02Shareholders Should Be Pleased With LSL Pharma Group Inc.'s (CVE:LSL) PriceWhen close to half the companies in the Personal Products industry in Canada have price-to-sales ratios (or "P/S...
お知らせ • Apr 09LSL Pharma Group Inc., Annual General Meeting, Jun 27, 2025LSL Pharma Group Inc., Annual General Meeting, Jun 27, 2025.
お知らせ • Mar 31LSL Pharma Group Appoints Louis Laflamme to the Board of DirectorsLSL PHARMA GROUP INC announce the appointment of Louis Laflamme as a member of the board of directors. Mr. Louis Laflamme is Entrepreneur in Residence for Medtech Ventures Fund of Sectoral Asset Management Inc. Previously, he was President, CEO and director of OpSens Inc. from January 2013 to March 2024, when it was acquired by Haemonetics for $345 million. During this period, the company revolutionized certain practices in interventional cardiology with medical instruments. From November 2005 to December 2012, he served as Chief Financial Officer and Corporate Secretary of OpSens. He also serves on the board of directors of SiliCycle, MY01 Inc., Icentia and EMKA SCIREQ Inc. He also held leadership positions in other technology companies. Mr. Laflamme is a member of the Order of Chartered Professional Accountants of Quebec. He holds a Bachelor's degree in Business Administration from Laval University.
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 40% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Shareholders have been substantially diluted in the past year (40% increase in shares outstanding). Minor Risk Market cap is less than US$100m (CA$43.3m market cap, or US$30.2m).
お知らせ • Dec 20LSL Pharma Group Inc. announced that it has received CAD 1 million in fundingLSL Pharma Group Inc. announced a private placement of unsecured promissory notes for a gross proceeds of CAD 1 million on December 18, 2024. The transaction included participation from new investor, Luc Mainville. The Notes are unsecured, non-convertible, bear interest at a blended rate of 13% and mature on January 1, 2028. The company has also issued 2,000,000 warrants in connection with the Notes, with each Warrant entitling the holder to purchase one common share of the Corporation at a price equal to the greater of CAD 0.70 or the closing price of the company on December 20, 2024 , for a period of 36 months following the closing of the Financing. The Notes may be redeemed by the Corporation at any time on or after January 1, 2026. Each Warrant and Warrant share will be subject to a four-month hold period under the applicable securities laws. The Financing is subject to the TSX Venture Exchange's approval. There were no finders involved with the Financing.
お知らせ • Dec 19LSL Pharma Group Inc. (TSXV:LSL) acquired Dermolab Pharma Ltd. for CAD 4 million.LSL Pharma Group Inc. (TSXV:LSL) acquired Dermolab Pharma Ltd. for CAD 4 million on December 17, 2024. The total consideration for the transaction includes (i) the renewal of Dermolab's operating line of credit and term loan totaling a maximum of $3 million and (ii) a cash payment of $955,000 on closing, subject to post-closing adjustments. The cash portion of the purchase price was financed by the proceeds of the CAD 2 million concurrent notes offering. For the period ending August 31, 2024, Dermolab Pharma Ltd. reported total revenue of CAD 10.1 million and EBITDA of CAD 0.5 million. As of August 31, 2024, Dermolab Pharma Ltd. reported total assets of CAD 7.9 million. Robert Boisvert, Dermolab's prior President has been retained for an interim period. The transaction is accretive, expected to boost revenues by approximately 40%. LSL Pharma Group Inc. (TSXV:LSL) completed the acquisition of Dermolab Pharma Ltd. for CAD 4 million on December 17, 2024.
お知らせ • Dec 18LSL Pharma Group Inc. Appoints Guy Paul Allard as Corporate SecretaryLSL PHARMA GROUP INC announced the appointment of Guy Paul Allard as Vice President, Legal Affairs and Corporate Secretary. A seasoned lawyer specializing in corporate and securities law for over 25 years, Mr. Allard has practiced in national and global law firms and has previously held similar executive in-house positions in the pharmaceutical industry.
分析記事 • Dec 14Not Many Are Piling Into LSL Pharma Group Inc. (CVE:LSL) Stock Yet As It Plummets 26%The LSL Pharma Group Inc. ( CVE:LSL ) share price has fared very poorly over the last month, falling by a substantial...
New Risk • Dec 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$5.7m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$5.7m free cash flow). Earnings have declined by 26% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (40% increase in shares outstanding). Market cap is less than US$100m (CA$47.4m market cap, or US$33.8m).
お知らせ • Nov 07LSL Pharma Group Announces Completion of Steri-Med Pharma's Phase 1 Production Scale UpLSL Pharma Group Inc. announced having completed the initial phase of production scale-up at its Steri-Med Pharma ("Steri-Med") plan. The initial phase of production scale up has contributed to more than double the plant capacity compared to 2023 levels, and enabled Steri-Med to win new international contracts for its existing products. The second phase of production scale-up will include the installation of a new fully automated sterile ointment production line (the "Second Line"). The Second Line is expected to be delivered during the first quarter of 2025 and to be operational early 2026, following installation and validation.
Reported Earnings • Aug 27Second quarter 2024 earnings released: CA$0.007 loss per share (vs CA$0.038 loss in 2Q 2023)Second quarter 2024 results: CA$0.007 loss per share (improved from CA$0.038 loss in 2Q 2023). Revenue: CA$4.19m (up 106% from 2Q 2023). Net loss: CA$516.0k (loss narrowed 83% from 2Q 2023).
お知らせ • Jul 15LSL Pharma Group Inc. announced that it has received CAD 2.4508 million in fundingOn July 15, 2024, LSL Pharma Group Inc closed the transaction. The company issued 2,400,000 units at a price of CAD 0.4 per Unit for total gross proceeds of CAD 960,000 in its final tranche. The Corporation was thus able to raise with both tranches a total of $2,450,800 in Financing. In connection with this second and final tranche of the Financing, the Corporation paid to finders dealing at arm’s length with the Corporation, finders’ fees for a total of CAD 14,600 in cash and issued 36,500 finders’ warrants. Each Finder’s Warrant entitles the holder to purchase one (1) Common Share at a price of CAD 0.70 for a period of 18 months following the closing date.
お知らせ • Jun 06LSL Pharma Group Inc. announced that it expects to receive CAD 3 million in fundingLSL Pharma Group Inc announced a non-brokered private placement financing of 7,500,000 units at issue price CAD 0.4 per share for gross proceeds CAD 3,000,000 on June 5, 2024. Each Unit consist of one class A share of the Corporation and one Common Share purchase warrant. Each Warrant will entitle the holder, subject to adjustments in certain cases, to purchase one Common Share at a price of CAD 0.70 for a period of 24 months following the closing of the Financing. Each issued Unit, Common Share, Warrant, Warrant Share, Finder’s Warrant and Common Share issued upon the exercise of the Finder’s Warrant will be subject to a four month hold period under the applicable securities laws. The Financing and the Units for Debts are subject to the regulatory approvals, including the TSX Venture Exchange.
お知らせ • May 18LSL Pharma Group Inc., Annual General Meeting, Jun 28, 2024LSL Pharma Group Inc., Annual General Meeting, Jun 28, 2024.
お知らせ • Apr 24LSL Pharma Group Inc. announced that it has received CAD 6.479426 million in funding from Alfera Pharmaceuticals, LLCOn April 24, 2024, LSL Pharma Group Inc. closed the transaction. The company has now issued 9,485,000 units at an issue price of CAD 0.40 per unit for the gross proceeds of CAD 3,794,000 in its second and final tranche closing bringing the total gross proceeds raised from the private placement to CAD 6,479,426. The company has now issued total 16,198,565 units for total gross proceeds of CAD 6,479,426 in the transaction. In connection with this transaction, the company paid to a finder dealing at arm’s length with the company, finders’ fees for a total of CAD 30,000 in cash and issued 75,000 finders’ warrants. Each Finder’s Warrant entitles the holder to purchase one common share at a price of CAD 0.70 for a period of 18 months following the closing of the transaction. Each issued unit, Common Share, Warrant, Warrant Share, Finder’s Warrant and Common Share underlying the Finder’s Warrants will be subject to a four month hold period under the applicable securities laws. The transaction is subject to the final approval of the TSX Venture Exchange. The transaction included participation from new investor Alfera Pharmaceuticals, LLC for 1,250,000 Units for an aggregate subscription price of CAD 500,000. Its direct or indirect holding, inclusive of Della Fera’s holding, on a non-diluted basis, was 0.04% prior to the financing and reaches now 1.20% following the financing while, on a partially diluted basis, was of 0.32% prior to the financing and reaches now 2.57%.
お知らせ • Apr 23LSL PHARMA GROUP INC Appoints Diane Beaudry and Mario Paradis to Its Board of DirectorsLSL PHARMA GROUP INC announced the appointment of Diane Beaudry and Mario Paradis to its Board of Directors.
New Risk • Mar 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 20% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (CA$37.9m market cap, or US$27.9m).
お知らせ • Mar 07LSL Pharma Group Inc. announced that it expects to receive CAD 3.5 million in fundingLSL Pharma Group announced a non brokered private placement financing of Units for the minimum of 6,250,000 units and maximum of 8,750,000 at an issue price of CAD 0.40 per unit for the minimum gross proceeds of CAD 2,500,000 and maximum of CAD 3,500,000 on March 7, 2024. Each unit will consists of one class A common share and one common share purchase warrant. Each Warrant will entitle the holder, subject to adjustments in certain cases, to purchase one Common Share at a price of CAD 0.70 for a period of 36 months following the closing of the Financing. the Corporation may pay finders’ fees of up to 5% of the gross proceeds raised from investors introduced to the Corporation by a finder, payable in cash; and finders’ warrants of up to 5% of the number of Units issued to investors introduced to the Corporation by a finder. Each Finder’s Warrant will entitle the holder, subject to adjustments in certain cases, to purchase one Common Share at a price of CAD 0.70 for a period of 18 months following the closing of the Financing. Each issued Unit, Common Share, Warrant, Warrant Share, Finder’s Warrant and Common Share issued upon the exercise of the Finder’s Warrant will be subject to a four month hold period under the applicable securities laws. The Financing and the Units for Debts are subject to the regulatory approvals, including the TSX Venture Exchange.
お知らせ • Dec 07LSL Pharma Group Inc., Annual General Meeting, Jan 26, 2024LSL Pharma Group Inc., Annual General Meeting, Jan 26, 2024.
お知らせ • Dec 04+ 1 more updateLSL Pharma Group Inc. Appoints Luc Mainville as Senior Vice President, Effective December 4, 2023LSL PHARMA GROUP INC announced the appointment of Mr. Luc Mainville as Senior Vice President and Chief Financial Officer effective December 4, 2023. Mr. Mainville brings extensive experience in the capital markets and life sciences industry. He is recognized for his financial and operational leadership having been associated with several fast-growing companies. In an executive management career spanning more than 30 years, he has been involved in numerous public and private financings totalling in excess of $500 million and more than 50 corporate transactions, including initial public offerings, licensing, as well as mergers and acquisitions. Over the last five years, Mr. Mainville acted as Senior Vice President and Chief Financial Officer of Valeo Pharma, a fast-growing Canadian pharmaceutical company. During his tenure at Valeo, he raised in excess of $100 million helping Valeo increase its revenues 15 fold. Prior to that, he held senior management positions with various life sciences companies, including Acerus Pharma, Cardiome Pharma, Neopharm Labs and LAB Research. Prior to his career in the life sciences sector, he was partner with KPMG, LLP. He holds an MBA from McGill University. Luc Mainville has been Director of LSL Pharma since February 2023, and will relinquish his board position when joining the Company.
Reported Earnings • Dec 03Third quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.023 loss in 3Q 2022)Third quarter 2023 results: CA$0.009 loss per share (improved from CA$0.023 loss in 3Q 2022). Revenue: CA$2.51m (down 4.9% from 3Q 2022). Net loss: CA$762.3k (loss narrowed 48% from 3Q 2022).
お知らせ • Sep 01LSL Pharma Group Inc. Announces Executive Changes, Effective August 31, 2023LSL Pharma Group announced the departure of Sylvain Richer, Chief Financial Officer, for personal reasons and to seek new opportunities, effective August 31, 2023. The Company has begun a process to find a successor. Untilthen, François Roberge will assume the interim and Mr. Richer will remain available to ensure a smooth transition.
New Risk • Aug 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Canadian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$4.2m free cash flow). Revenue has declined by 6.3% over the past year. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (CA$33.7m market cap, or US$24.9m).
New Risk • Jul 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 7.6% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (CA$35.4m market cap, or US$26.7m).
Board Change • Mar 03No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Luc Mainville was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
